NCT04300556 · Interventional trial
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Overall registry status Recruiting
Phase 1 · Phase 2
Conditions Solid Tumor
Delaware Valley sites
- MD Anderson Cancer Center at Cooper · Camden, NJ · Camden County · Completed
First posted
Registry updated
Added to the directory